The license grants Medarex non-exclusive rights to research, develop and commercialize therapeutic antibodies based on Complegent technology for an undisclosed number of targets.
In return, BioWa will receive upfront payment, license fees, development milestone payments and royalties on products.
Howard Pien, president and CEO of Medarex, said: “We are excited about the possibility of enhancing our antibodies with BioWa’s technology platform. Our partnership grants Medarex the first access to Complegent technology and we look forward to investigating its potential as we continue to advance our pipeline.”